Amphastar Pharmaceuticals (NASDAQ:AMPH) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.03 per share for the quarter.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.07. Amphastar Pharmaceuticals had a return on equity of 5.14% and a net margin of 0.74%. The firm had revenue of $79.79 million during the quarter, compared to analyst estimates of $76.21 million. During the same period last year, the company earned $0.05 EPS. Amphastar Pharmaceuticals’s quarterly revenue was up 36.7% compared to the same quarter last year. On average, analysts expect Amphastar Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of AMPH stock traded up $0.22 on Tuesday, reaching $19.58. 8,260 shares of the company’s stock were exchanged, compared to its average volume of 145,887. Amphastar Pharmaceuticals has a 52 week low of $16.18 and a 52 week high of $25.43. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.11. The company has a market cap of $935.19 million, a PE ratio of 92.76 and a beta of 1.35. The business has a fifty day moving average of $20.26.
AMPH has been the subject of a number of research analyst reports. BidaskClub raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Wednesday, July 10th. Finally, Wells Fargo & Co set a $29.00 target price on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 6th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Amphastar Pharmaceuticals has an average rating of “Buy” and an average target price of $24.64.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.